SBIR/STTR Research Award

A New Treatment to Reduce Scarring

Award identifier 53f7e386f1101aaf0f963d68fb8c8e7b63baef28eb5a4152ae6280616d428cc8Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$306,161

Program and phase

SBIR · Phase I

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Kalyra Pharmaceuticals, Inc.
Proposal award date
2016-05-15
Contract end date
2017-11-14
UEI
JW3AWK3ATUE9
Solicitation number
PA14-071
Topic code
300

Research abstract

DESCRIPTION provided by applicant Tissue scarring associated with poor wound healing can be a serious problem particularly when the scarring is in the eye The exposed cornea is first to become involved in ocular infection chemical or blast injuries Worldwide corneal diseases primarily resulting from infection trauma and surgical complications are responsible for to million cases of blindness in human patients Poor corneal wound healing can result in permanent loss of corneal transparency and vision loss Currently there are limited medical and surgical treatments available to address this problem Kalyra Pharmaceuticals has developed a series of novel potent anti scarring anti fibrotic compounds utilizing our toolbox of proprietay bioisosteres With lead candidates in hand we aim to demonstrate that these molecules can reduce scarring of the cornea after injury via the Phase I proof of concept studies outlined below Phase I Demonstrate Reduction of Scarring in a Model of Corneal Wound Healing Aim Preliminary formulation development for topical delivery to the eye Aim Determine the extent of drug uptake in the cornea after topical administration Aim Demonstrate efficacy by reducing scarring in a model of corneal wound healing Goal Proof of concept for significant reduction of scarring of the cornea and characterization of drug uptake in the cornea after topical administration After the successful completion of the studies described in this Phase I application we will continue the non clinical development of a new treatment for reduction of fibrosis and scarring in the eye in Phase II PUBLIC HEALTH RELEVANCE This project is focused on demonstrating proof of concept for a new treatment to reduce scarring Poor corneal wound healing and scarring in the eye can result in permanent loss of corneal transparency and there are limited medical treatments available to address this problem The purpose of this proposal is to develop a novel treatment to improve the healing of corneal wounds and reduce the extent of corneal scarring Such a new therapy may profoundly alter how we treat corneal wounds in people in the future A new treatment that reduces scarring can also be applied to other indications where improved wound healing is required

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

4 SBIR/STTR records share this UEI (2015–2017). Reported award amounts total $4,073,230. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.